公开(公告)号：US10767230B2

公开(公告)日：2020-09-08

申请号：US15501691

申请日：2015-08-11

Applicant: Agency for Science, Technology and Research ,  National University of Singapore ,  National University Hospital (Singapore) Pte Ltd

Inventor： Heng-phon Too ,  Lihan Zhou ,  Ruiyang Zou ,  Khay Guan Yeoh ,  Bok Yan So ,  Feng Zhu ,  Wei Peng Yong

IPC: C12Q1/6886 ,  G16B25/00 ,  G16B20/00 ,  G01N33/574 ,  G16H50/20

Abstract: Disclosed are methods of determining the likelihood of a subject having or developing a gastric cancer. The methods comprise measuring the expression level of at least one miRNA having at least 90% sequence identity with an miRNA as described herein in a non-cellular biofluid sample obtained from the subject, wherein differential expression of miRNA expression in the sample obtained from the subject, as compared to a control, may be indicative of the subject having gastric cancer and wherein the miRNA may be either an miRNA listed as “up-regulated” or an miRNA listed as “down-regulated”. Also disclosed is a method of determining the likelihood of a subject having or developing a stage of a gastric cancer.

公开(公告)号：US12188092B2

公开(公告)日：2025-01-07

申请号：US15557457

申请日：2016-03-09

Applicant: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH

Inventor： Heng-Phon Too ,  Lihan Zhou ,  Ruiyang Zou

IPC: C12Q1/6886

Abstract: The present disclosure describes methods of determining the risk of developing breast cancer in a subject or determining whether a subject suffers from breast cancer. The methods can comprise detecting the expression level of microRNAs (miRNAs) hsa-miR-186-5p (SEQ ID NO: 77) and/or hsa-miR-409-3p (SEQ ID NO: 178) in a bodily fluid sample obtained from the subject and determining whether it is upregulated or downregulated as compared to a control, wherein the upregulation of hsa-miR-186-5p (SEQ ID NO: 77) and/or downregulation of hsa-miR-409-3p (SEQ ID NO: 178) indicates that the subject has breast cancer or is at risk of developing breast cancers. Also encompassed are methods of prognosis or diagnosis of breast cancer by detecting expression levels of combinations of miRNAs and using a score based on a panel of miRNA markers.

公开(公告)号：US20230313308A1

公开(公告)日：2023-10-05

申请号：US17713143

申请日：2022-04-04

Applicant: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH ,  Singapore Health Services Pte Ltd ,  National University Hospital (Singapore) Pte Ltd ,  Tan Tock Seng Hospital Pte Ltd ,  MiRXES Lab Pte. Ltd.

Inventor： Siew Gek Lee-Lim ,  Ruiyang Zou ,  Lihan Zhou ,  He Cheng ,  Bo Anders Mikael Hartman ,  Heng-Phon Too

IPC: C12Q1/6886

CPC classification number: C12Q1/6886 ,  C12Q2600/112 ,  C12Q2600/178 ,  C12Q2600/158 ,  C12Q2600/118

Abstract: This technology relates to a method of treating breast cancer in a subject and a method of determining whether a breast lesion in a subject is malignant or benign using miRNA panels.

公开(公告)号：US10100331B2

公开(公告)日：2018-10-16

申请号：US14439330

申请日：2013-10-29

Applicant: Agency for Science, Technology and Research ,  National University of Singapore

Inventor： Heng-Phon Too ,  Yoon Khei Ho ,  Lihan Zhou

IPC: C12N15/87 ,  C12N15/85 ,  C12N5/00 ,  A61K31/7084 ,  A61K48/00 ,  A61K31/711 ,  A61K47/34 ,  A61K9/127 ,  A61K39/00

Abstract: The present invention relates to a composition for transfecting a cell with a genetic material comprising a first agent capable of directing the genetic material away from the acidic compartments in the cell and a second agent capable of stabilizing the microtubule or a network thereof. The invention also relates to the use of the composition in the manufacture of a medicament for treating a disease, a method for delivering a genetic material into a cell and a kit.

公开(公告)号：US20150361449A1

公开(公告)日：2015-12-17

申请号：US14439330

申请日：2013-10-29

Applicant: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH ,  NATIONAL UNIVERSITY OF SINGAPORE

Inventor： Heng-Phon Too ,  Yoon Khei Ho ,  Lihan Zhou

IPC: C12N15/85

CPC classification number: C12N15/85 ,  A61K9/1272 ,  A61K31/711 ,  A61K39/0011 ,  A61K47/34 ,  A61K48/00 ,  A61K2039/5152 ,  A61K2039/5156 ,  A61K2039/55522 ,  C12N15/87

Abstract: The present invention relates to a composition for transfecting a cell with a genetic material comprising a first agent capable of directing the genetic material away from the acidic compartments in the cell and a second agent capable of stabilizing the microtubule or a network thereof. The invention also relates to the use of the composition in the manufacture of a medicament for treating a disease, a method for delivering a genetic material into a cell and a kit.

Abstract translation: 本发明涉及一种用遗传材料转染细胞的组合物，其包含能够将遗传物质远离细胞中的酸性隔室的第一种试剂和能够稳定微管或其网络的第二种试剂。 本发明还涉及组合物在制备用于治疗疾病的药物中的用途，将遗传物质递送到细胞和试剂盒中的方法。